Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Is BPC 157 Banned? Oral vs. Injectable Forms Explained The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance[v3] Preprints.org